UNITED-ENGINE-CORP
The Russian-French SaM146 engine that powers Sukhoi Superjet 100 (SSJ100) airliners has logged over 620 thousand flight hours in operation. The SaM146 engine, produced within the 50/50 partnership between Safran and UEC, is successfully operated all around the world by well-known airlines such Russian Aeroflot, Mexican Interjet and Irish CityJet.
UEC and Safran, PowerJet mother companies, are both exhibiting SaM146 engines at their respective stands at Paris Air Show 2017 in Le Bourget (France).
SaM146 is an integrated power plant which includes the engine and the nacelle equipped by a thrust reverser. The deliveries of SaM146 and all the after-sales services are performed by PowerJet, a joint venture formed on the principles of equal representation by Safran Aircraft Engines and Russian UEC-Saturn (a part of the United Engine Corporation, UEC). UEC-Saturn is a developer and producer of the fan, the low-pressure compressor and the low-pressure turbine, and is also responsible for the final engine assembly and its testing. Safran Aircraft Engines is a developer and producer of the high-pressure compressor, the combustion chamber, the high-pressure turbine, the gearbox, the FADEC system. The French company also performs the overall integration of the power plant and is responsible for the final engine assembly and ground tests.
The leading engine of Yakutia Airline has reached 7,800 flight hours; the leading Interjet engine has surpassed 6,400 flight cycles.
Since starting revenue service in 2011, the SaM146 engine has demonstrated the exceptional performance in service, with an engine dispatch reliability of 99,9%. Such performance is based on Safran Aircraft Engines and UEC experience in commercial engines to develop the SaM146. Its optimised design improves performance and facilitates on wing maintenance to keep up with the best rate of availability.
SaM146-powered SSJ100 are currently used by 15 operators. Some of them are conducting very intensive operations in harsh environments
In order to build the world class after-sales support system, two spare part distribution centres are operating in Russia (Lytkarino) and France (Villaroche). Such localisation of the warehouses lets us to deliver spare parts practically anywhere around the world in 24 hours. Two training facilities for airlines' technical personnel also function there. The round the clock customer support centre and a web-portal are also in operation.
The SaM146 is offered in two versions which are developed and certified in accordance with the Russian and European requirements: 1S17 and 1S18 for SSJ100-95B, SSJ100-95LR and SSJ100 B100 planes, 1S17С and 1S18С for VIP-versions of SSJ100.
UEC (United Engine Corporation, a part of the Rostec State Corporation) is specialising in development, serial production, service and support of engines for military and civil aviation, space programmes and navy, as well as oil and gas industry and power generation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170621005657/en/
Contact:
United Engine Corporation
Alexander Artyukhov
press@uecrus.com
Tel.
+7 (499) 558-38-83
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom